Antimicrobial kinocidin compositions and methods of use
View Patent ↗The present invention provides novel kinocidin peptides comprising a C-terminal portion of a kinocidin, wherein the C-terminal portion encompasses an α-helical secondary structure and further displays antimicrobial activity. The kinocidin peptides of the invention are derived from and correspond to a C-terminal portion of a kinocidin that includes a γκo core and that can be a CXC, CC, or C class chemokine. Structural, physicochemical and functional properties of this novel class of antimicrobial peptides and amino acid sequences of particular kinocidin peptides are also disclosed. The invention also provides related antimicrobial methods.
1. A method for treating an infectious disease or condition in a subject in need of such treatment comprising administering to the subject an effective amount of a peptide which (a) is 50 amino acid residues or less in length, (b) comprises a C-terminal portion α-helical amino acid sequence of a kinocidin and a γKC core motif of the formula:
NH 2 [C]-[X 10-13 ]-[GX 2-3 C]-[X 2 ]-[P]COOH, (SEQ ID NO:39)
wherein X represents any amino acid, and (c) has antimicrobial activity, wherein said kinocidin is a CXC, CX 3 C, CC, or C class chemokine and comprises a γKC core.
2. The method of claim 1 , wherein said α-helical amino acid sequence comprises KENWVQRVVEKFLKRAENS (SEQ ID NO: 1).
3. The method of claim 1 , wherein said α-helical amino acid sequence comprises QAPLYKKIIKKLLES (SEQ ID NO: 2).
4. The method of claim 1 , wherein said α-helical amino acid sequence comprises ASPIVKKIIEKMLNSDKSN (SEQ ID NO: 3).
5. The method of claim 1 , wherein said α-helical amino acid sequence comprises an amino acid sequence selected from the group consisting of QATWVRDVVRSMDRKSNTRNN (SEQ ID NO: 38), ASPMVKKIIEKMLKNGKSN (SEQ ID NO: 5), EAPFLKKVIQKILDGGNKEN (SEQ ID NO: 7), EAPFLKKVIQKILDSGNKKN (SEQ ID NO: 8), DAPRIKKIVQKKLAGDESAD (SEQ ID NO: 9), DSADVKELIKKWEKQVSQKKKQKNGKK (SEQ ID NO: 359), ESKAIKNLLKAVSKERSKRSP (SEQ ID NO: 10), KSKQARLIIKKVERKNF (SEQ ID NO: 11), KLKWIQEYLEKALNKRFKM (SEQ ID NO: 12), QAEWIQRMMEVLRKRSSSTLPVPVFKRKIP (SEQ ID NO: 13), TVGWVQRHRKMLRHCPSKRK (SEQ ID NO: 15), KERWVRDSMKHLDQIFQNLKP (SEQ ID NO: 21), KEKWVQNYMKHLGRKAHTLKT (SEQ ID NO: 23), SDKWVQDYIKDMKEN (SEQ ID NO: 24), SGPGVQDCMKKLKPYSI (SEQ ID NO: 25), NNKRVKNAVKYLQSLERS (SEQ ID NO: 27), NKKWVQKYISDLKLNA (SEQ ID NO: 28), DQPWVERIIQRLQRTSAKMKRRSS (SEQ ID NO: 29), SDKQVQVCVRMLKLDTRIKTRKN (SEQ ID NO: 33), KQEWVQRYMKNLDAKQKKASPRAR (SEQ ID NO: 34), KQKWVQDSMDHLDKQTQTPKT (SEQ ID NO: 16), SEEWVQKYVSDLELSA (SEQ ID NO: 17), SESWVQEYVYDLELN (SEQ ID NO: 18), EKKWVREYINSLEMS (SEQ ID NO: 19), TQKWVQDFMKHLDKKTQTPKL (SEQ ID NO: 20), KKKWVQDSMKYLDQKSPTPKP (SEQ ID NO: 22), NDDWVQEYIKDPNLPLLPTRNLSTVKII (SEQ ID NO: 26), KQTWVKYIVRLLSKKVKNM (SEQ ID NO: 30), KELWVQQLMQHLDKTPSPQKPAQG (SEQ ID NO: 31), RVPWVKMILNKLSQ (SEQ ID NO: 32), KSREVQRAMKLLDARNK (SEQ ID NO: 35), QNPSLSQWFEHQERKLHGTLPKLNFGMLRKMG (SEQ ID NO: 36), and HNHTVKQWMKVQAAKKNGKGN (SEQ ID NO: 37).
6. The method of claim 1 , wherein said α-helical amino acid sequence comprises between 10 and 35 amino acids.
7. The method of claim 1 , wherein said α-helical amino acid sequence has a mass between 1100 Da and 3850 Da.
8. The method of claim 1 , wherein said α-helical amino acid sequence has a calculated charge between 0 and (+) 5 at pH 7.0.
9. The method of claim 1 , wherein said α-helical amino acid sequence has an estimated isoelectric point between 5 and 15.
10. The method of claim 1 , wherein said α-helical amino acid sequence has a hydrophobic moment between 3 and 8.
11. The method of claim 1 , wherein the γKC core motif has the formula:
NH 2 CX 4 Z 3 X 0-2 KX 1-3 G[K/R]BZCZ[D/N]PCOOH, (SEQ ID NO:41)
wherein:
Z represents an amino acid selected from the group consisting of A, F, I, L, V, W, and Y;
B represents an amino acid selected from the group consisting of D, E, H, K, N, R and Q; and
X represents any amino acid.
12. The method of claim 1 , wherein the peptide is 40 amino acid residues or less in length.